Biopharma | November 14, 2025
Transition Bio and Voyager Therapeutics forge strategic collaboration to target ALS, FTD
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
From material selection to cooling tower management, every small decision affects long-term equipment reliability
Dr. Jindal reflects on bridging accessibility gaps between urban and rural regions, the ethical and emotional aspects of family building, and how initiatives like adoption facilitation centers align with his lifelong mission to help couples realize the dream of parenthood
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
Subscribe To Our Newsletter & Stay Updated
